0001326110-24-000013.txt : 20240202 0001326110-24-000013.hdr.sgml : 20240202 20240202193245 ACCESSION NUMBER: 0001326110-24-000013 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240131 FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LAUER REGAN J CENTRAL INDEX KEY: 0001200637 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37507 FILM NUMBER: 24593501 MAIL ADDRESS: STREET 1: 4250 EXECUTIVE SQUARE SUITE 300 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER NAME: FORMER CONFORMED NAME: GALLAGHER REGAN J DATE OF NAME CHANGE: 20021023 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ImmunityBio, Inc. CENTRAL INDEX KEY: 0001326110 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 431979754 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3530 JOHN HOPKINS COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (844) 696-5235 MAIL ADDRESS: STREET 1: 3530 JOHN HOPKINS COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: NantKwest, Inc. DATE OF NAME CHANGE: 20150713 FORMER COMPANY: FORMER CONFORMED NAME: Conkwest, Inc. DATE OF NAME CHANGE: 20140416 FORMER COMPANY: FORMER CONFORMED NAME: ZelleRx Corp DATE OF NAME CHANGE: 20050504 4 1 wk-form4_1706920344.xml FORM 4 X0508 4 2024-01-31 0 0001326110 ImmunityBio, Inc. IBRX 0001200637 LAUER REGAN J C/O IMMUNITYBIO, INC. 3530 JOHN HOPKINS COURT SAN DIEGO CA 92121 0 1 0 0 Chief Accounting Officer 0 Common Stock 2024-01-31 4 M 0 32872 0 A 107804 D Common Stock 2024-01-31 4 F 0 13470 3.36 D 94334 D Restricted Stock Units 2024-01-31 4 M 0 32872 0 D Common Stock 32872 0 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award vested on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award vested on January 31, 2024. /s/ Jason Liljestrom, as Attorney-in-Fact 2024-02-02